This month we have several new and important items for you at the HCV and HBV Websites:
This eblast has information about the first interferon-free phase III data of GS-7977 plus ribavirin to treat HCV genotype 2, and 3 with an SVR of 78%. Treatment duration was 12 weeks. This is a milestone moment in the history of and treatment for HCV—following in the footsteps of this combination are more DAA combinations without interferon in mid-stage development
Gilead hepatitis C drug shows promise in late-stage trial
1. December 2012 HCV Advocate
In This Issue:
- AASLD 2012 Part 1: HCV Therapies
Alan Franciscus, Editor-in-Chief: In Part 1 of AASLD conference coverage I concentrate on the DAA combination therapies without interferon—some of which did not even include ribavirin!
- HCV Snapshots: AASLD 2012
Lucinda K. Porter, RN: Lucinda's conference coverage includes many interesting presentations such as drug-drug interactions with boceprevir and telaprevir, confusion with acetaminophen labeling, and an interesting study on the differences in response rates between men and women and much, much more.
- HealthWise: - 2012 Liver Meeting Update
Lucinda K. Porter, RN: This month's "HealthWise" features commentary about AASLD and some thoughts about giving to HCV organizations.
- Disability & Benefits:Are There Benefits to a Reverse Mortgage?
Jacques Chambers, CLU: Reverse mortgages have been in the news lately – there are lots of pitfalls for people unless they are carefu. Jacques writes about the pros and cons, and in a word – be careful.
2. HBV Journal Review by Christine Kukka —In this month's column Chris reviews the following studies. Hepatitis B is a complicated disease to understand and manage. Christine's monthly review provides much needed information to stay up to date and live healthy with hepatitis B :
- Vaccination May Not Protect Against HBV with Surface Antigen Mutation
- HBV-Infected Fathers Appear Not to Pose Infection Risk to Fetuses
- Genotype B Prone to Chronic Infection, and Genotype D Prone to Liver Cancer Despite Treatment
- Lamivudine Results Raising Concern Among Researchers
- HBeAg Seroconversion Rate Lower with Entecavir Than Earlier Reported
- Environmental Toxin Dramatically Increases Liver Cancer in Asia and Africa
- Antivirals Reduce Liver Cancer Risk in Some–But Not All
- Because It Can Be Reversed, New Terminology Needed to Describe Cirrhosis
- Depression During Interferon More Severe in Hepatitis C Than Hepatitis B Patients
- Nearly Half of HBV-Infected Children Eventually Lose HBeAg–With or Without Treatment
- Researchers Identify the Protein Doorway That Allows HBV to Infect Liver Cells
- Tenofovir Used to Treat Many Newly-Infected with Multi-Drug Resistant HBV
- Another Study Links Hepatitis B and Diabetes
3. HCV Drug Pipeline – has been updated to include the most recent news items.
U.S. Preventive Services Task Force
The U.S. Preventive Services Task Force makes recommendations for testing for certain conditions and diseases. Their recommendations can affect whether a physician will order a test or even alert their patients that there may be a disease that they could or should be tested for.
Please read the draft statement carefully. There is a link on the right-hand side of the page that will take you to a webpage that will allow you to make comments.
Please let U.S. Preventive Services know what you think about their recommendations whether you agree or disagree with their recommendations or if you think the language and recommendations should be stronger. It could make a difference in how USPSTF recommends testing for HCV.
5. Training Schedule – Don’t forget to keep checking our Upcoming Training Workshop Schedules to see if we will be in your neighborhood soon!
Don’t forget that there is help as close as a phone call – the 877-HELP-4-HEP line (877-435-7443) is available 9:00am to 7:00pm Eastern Time. For more information about the services they offer either call or visit their Website at www.help4hep.org The helpline is run by The Support Partnership: a group of non-profits working together to help people affected by hepatitis C.
7. Top News (Blog) from the hepatitis blog includes:
and much, much more…..
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org
**Questions and Comments: Questions and/or comments can be directed to email@example.com
**To receive the eblast in your email inbox simply send an e-mail to: firstname.lastname@example.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.